Skip to main content

Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

Written by Customer Service on . Posted in Public Companies.

Chief Executive Officer, Chief Technical Officer, Chief Medical Officer and Head of Research and Development and Senior Vice President of Manufacturing to participate in a panel discussion at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2022 at 12:00 pm ET

Chardan Genetic Medicines and Cell Therapy Manufacturing Summit Fireside Chat on April 25, 2022 at 1:00 pm ET

DALLAS, April 18, 2022 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the upcoming panel and fireside chat at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit.

Conference Details:
   
Event: Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
   
Topic: Evolving standards of AAV GT manufacturing – learnings from experience in registration-targeted trials
   
Date: Monday, April 25, 2022
   
Time: 12:00 pm ET
   
Format: Panel Discussion
   
Participants: RA Session II, President, Founder and CEO
   
  Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
   
  Dr. Frederick Porter, Chief Technical Officer
   
  Greg Gara, SVP, Manufacturing

Conference Details:
   
Event: Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
   
Date: Monday, April 25, 2022
   
Time: 1:00 pm ET
   
Format: Fireside Chat
   
Participants: RA Session II, President, Founder and CEO
   
  Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
   
  Kamran Alam, Chief Financial Officer


About Taysha Gene Therapies        

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com

Media Contact:
Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.